Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate

Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate is a frequently cited building block in medicinal chemistry programs targeting kinases, phosphodiesterases, and GPCRs. The compact [4,3‑c] ring fusion of Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate places the ester and the tetrahydropyran oxygen in a favorable spatial arrangement for intramolecular hydrogen bonding, which can influence both conformation and target recognition. Researchers utilize Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate as a late‑stage intermediate that can be rapidly elaborated through ester aminolysis, hydrolysis, or reduction to generate focused libraries of pyrazole‑based inhibitors. The commercial availability of Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate in high purity reduces the burden of in‑house synthesis and allows discovery teams to concentrate on SAR expansion rather than core construction.

Product Parameters

Product Advantages

1. Fused Pyranopyrazole Core – Provides a rigid yet partially saturated scaffold that enhances solubility and metabolic stability relative to fully aromatic analogs.

2. Three Functional Handles – The ester, pyran oxygen, and the two pyrazole nitrogens offer distinct derivatization points for selective elaboration.

3. Defined Regiochemistry – The 1,4,6,7‑tetrahydro substitution pattern is confirmed by NOE or X‑ray analysis to avoid ambiguity.

4. Medicinal Chemistry Enabler – Found in intellectual property covering ATP‑competitive kinase inhibitors and CNS‑active agents.

5. Pharma‑Compliant Supply Chain – Packaged, shipped, and documented in accordance with pharmaceutical intermediate standards.

FAQ

Q1: What is the most common use of this intermediate?

A: It is predominantly used to prepare kinase inhibitors, where the pyranopyrazole core acts as a hinge‑binding motif, and the ester is converted to amide or acid for target engagement.

Q2: Is there any concern about regioisomer formation?

A: The ethyl ester is located at the 3‑position of the pyrazole, and our process controls the cyclization to avoid formation of the alternative 1,4,5,6‑ or 1,4,6,6‑tetrahydro isomers.

Product Quality Assurance

Cosperpharm releases Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate against a specification that includes HPLC purity (≥98.0%), appearance, melting point, and residue on ignition. A comprehensive analytical package (CoA, NMR spectrum, HPLC chromatogram) is provided with each order. We maintain stability‑indicating methods and can share forced degradation data upon request.

Contact Us

From early discovery to IND‑enabling studies, let Cosperpharm be your partner for this versatile pyranopyrazole scaffold. Contact our sales office today to discuss availability, custom pack sizes, or technical documentation.